Syndax Pharmaceuticals (SNDX) Equity Average: 2016-2025
Historic Equity Average for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Sep 2025 value amounting to $136.4 million.
- Syndax Pharmaceuticals' Equity Average fell 65.93% to $136.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $136.4 million, marking a year-over-year decrease of 65.93%. This contributed to the annual value of $421.2 million for FY2024, which is 17.55% down from last year.
- Syndax Pharmaceuticals' Equity Average amounted to $136.4 million in Q3 2025, which was down 26.75% from $186.2 million recorded in Q2 2025.
- In the past 5 years, Syndax Pharmaceuticals' Equity Average registered a high of $523.0 million during Q1 2024, and its lowest value of $136.4 million during Q3 2025.
- In the last 3 years, Syndax Pharmaceuticals' Equity Average had a median value of $400.4 million in 2024 and averaged $363.1 million.
- Its Equity Average has fluctuated over the past 5 years, first soared by 464.44% in 2021, then slumped by 65.93% in 2025.
- Over the past 5 years, Syndax Pharmaceuticals' Equity Average (Quarterly) stood at $303.7 million in 2021, then soared by 32.63% to $402.8 million in 2022, then climbed by 13.39% to $456.7 million in 2023, then fell by 28.34% to $327.3 million in 2024, then crashed by 65.93% to $136.4 million in 2025.
- Its Equity Average was $136.4 million in Q3 2025, compared to $186.2 million in Q2 2025 and $251.6 million in Q1 2025.